🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Big Dumb Line ft. Joe Jonas

It’s going to be again another #TrastuzumabDeruxtecan #TDXd year…looking forward to the full results including safety ! astrazeneca.com/media-centre/p… OncoAlert #BreastCancer #bcsm

Another positive trial in #bcsm, TDXd followed by THP beats ddAC-THP in neoadjuvant HER-2+ early breast cancer. We've seen a lot of positive TDXd results, but this is the FIRST 🥇in the early stage setting! Oncology Brothers OncoAlert astrazeneca.com/media-centre/p…

Found a The Leukemia & Lymphoma Society cupcake at Georgetown Cupcakes. I had to buy it!!

The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸 ⭐ LBA1008: DESTINY-BREASTO9: TRASTUZUMAB DERUXTECAN (T-DXD) + PERTUZUMAB (P) VS TAXANE + TRASTUZUMAB

Started #ASCO25 with the OncoAlert race. Originally intended for 5k but I got a little too excited.

And there you have it folks the standard of care has been changed #ASCO25 #TNBC #MBC

#ASCO25 today: Thrilled to present our findings from the GBD ‘21 study highlighting key trends in US #breastcancer mortality over the past 30 yrs: 🥩 Red meat remains the leading contributor. 🚭 ASMR from tobacco & alcohol is declining, especially among premenopausal women. 📈

Very valuable session at PER about HR+/HER2- mbc led by William Gradishar, MD , Dr Yuan and Laura Huppert, MD . #ASCO25 #bcsm

PROMISE: randomized window (28d) trial of conjugated estrogens + bazedoxifene (duavee) v placebo in ER+DCIS. -⬇️Ki67 -no change in QoL -⬇️ hot flashes -supports CE/BZA as an HRT option in post menopausal women and testing its potential in breast ca risk reduction

NATALEE update Kevin Kalinsky, MD, MS, FASCO ✅Consistent benefit across menopausal status and age ✅Manageable safety profile across all subgroups ⬇️Ribo discontinuation due to AE in younger premenopausal pts ✅Maintained QoL for all subgroups #ASCO25 #bcsm Oncology Brothers OncoAlert

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

SERENA-6 trial takeaways from ⁦Angie DeMichele, MD, MSCE, FASCO⁩

#SERENA6 and how it fits in to current landscape for fellows 💡 ➡️1L HR+ HER-2 (-) MBC SOC: CDK4/6 + AI or fulvestrant- here most pts received palbociclib - at least 6mo ESR1 detected on ctDNA AHEAD of progression & if detected added Camizestrant (oral SERD) ➡️met PFS #ASCO25

The curves everybody’s been waiting for. First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.

#ASCO25 Poster Session on #MBC 👉 #DATOBase: A phase II study of DATOpotamab deruxtecan for patients with #BreastCancerBrainMetastases or #Leptomeningeal disease. Abs TPS1134 | Post Bd 106a| Jun 2 9-12 PM CDT | Hall A Paolo Tarantino Dr Sarah Sammons Sara Tolaney Nancy Lin, MD

Happening Now! #ASCO25 Poster Session: Updated efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA-mutant HR+HER2- advanced #BreastCancer: ReDiscover trial. Dr Sarah Sammons 📍Abs: 1086 | Poster Bd 65 | Jun 2, 9-12 PM | Hall A

Congratulations to our amazing first year fellow Jorge Avila, MD Jorge presenting the effect of body weight and body composition in metastatic breast cancer patients survival and toxicities🥳🥳 #ASCO2025 #BreastCancer #hemeoncfellows #montefiorehemeonc

Last day at #ASCO25 and happy to have presented our poster on body composition and PFS in #MBC , to have met new colleagues and re-connected with old friends. Now back to NYC #bcsm

🚨 Exercise is no longer optional, it is essential! One of the most impactful studies at #ASCO25 🏃‍♂️ The #CHALLENGE trial (LBA4319) proves that structured exercise after chemo in stage III colon cancer is not just lifestyle—it’s life-saving. 📊 5y DFS: 80.3% vs 73.9% ❤️ 8y OS: